Karnataka Government to Re-examine Hospital Drug Price Disclosure Circular

Bengaluru, October 30, 2026: The Karnataka government told the Karnataka High Court on Friday that it will re-examine its October 1 circular requiring hospitals to disclose the landing or base price of medicines and devices in patient bills, a proposal rooted in the wider discussion around drug price control, and that it will not insist on compliance before the next hearing. The assurance effectively pauses the November 1 start date that the Food Safety and Drug Administration had fixed for the new billing requirement.

The circular was issued on October 1, 2026, by the Food Safety and Drug Administration. It directed hospitals and healthcare institutions across the state to show the landing or base price of medicines, medical devices and consumables in the bills given to patients. The stated aim was to improve price transparency and guard patients against unfair mark-ups on products supplied during treatment.

Under the plan, a patient bill would have carried more than the maximum retail price and the amount charged by the hospital. It would also have shown the price at which the hospital had itself procured the item. The government position was that such disclosure would allow patients and families to see the gap between procurement cost and the final charge.

The matter came up before the High Court on October 30. The government informed the court that it intends to look at the circular afresh. It also gave an assurance that no hospital would be compelled to follow the October 1 directions until the court takes up the matter again. The court took the statement on record.

No final order on the validity of the circular was passed on Friday. The case will be heard again on the next date fixed by the court. Till then, the position as stated by the government is that the circular will remain on paper but will not be enforced.

Billing Disclosure Plan From November 1

The October 1 circular had set November 1 as the date from which disclosure was to begin. Hospitals were expected to adjust their billing software and internal processes to capture procurement prices and print them on patient bills. For large hospitals that purchase thousands of drug formulations, devices and consumables, the change involved back-office work and coordination with pharmacies and suppliers.

The Food Safety and Drug Administration linked the move to patient interest. The view within the department was that patients admitted to hospitals often have little choice about the brand of medicine, implant or consumable used in the course of care. Disclosure of the base price, it was felt, would give patients information that is normally not available at the point of billing.

Hospitals, on the other hand, have raised questions about the burden involved in such disclosure. Their concern relates to the volume of items used in daily care, frequent changes in procurement rates, and the need to map purchase invoices to individual patient bills. The balance between transparency for patients and workability for institutions is now at the centre of the dispute.

For patients, the issue is direct. A hospital bill often includes charges for drugs given during admission, surgical consumables, implants, syringes, catheters and other items. Most patients see only the final amount and the maximum retail price printed on a pack, where applicable. They do not see what the hospital paid to procure the same item.

Supporters of disclosure say that showing the landing price would help families understand the mark-up and ask questions where the difference appears large. They point to instances where patients have complained about high charges for medicines and consumables supplied inside hospitals, particularly during long admissions, emergency care and surgeries. In that sense, billing detail is seen as a patient right.

Others point out that retail price comparison has become common for the public. The habit mirrors everyday price searches by consumers, from a patient in Bengaluru comparing a hospital bill to someone typing birth control pills philippines mercury drug price into a search box to check retail cost, though hospital procurement and retail sale operate under different rules. Hospital billing, they say, involves storage, handling, quality checks and service costs that a simple over-the-counter purchase does not carry.

drug price control powers and hospital billing

The legal backdrop involves the powers available to regulate prices and conditions of sale of drugs and medical devices. India has a central framework for drug price control that fixes ceiling prices for scheduled formulations and monitors maximum retail prices. Separately, state drug control and food safety authorities act against sale of substandard or misbranded drugs and enforce labelling and licensing conditions.

The Karnataka circular did not itself fix the price at which hospitals must sell. It sought disclosure of the procurement price as part of the bill. The distinction matters in law. A disclosure requirement is different from a price cap. It does not tell a hospital what to charge, but it requires the hospital to share information about cost alongside the charge.

Questions that courts usually examine in such matters include whether the issuing authority had the power to impose the condition, whether the direction was issued in the prescribed manner, and whether the burden placed on those regulated is reasonable. Courts also look at whether a circular creates a new legal obligation without support in the parent law, rules or licence conditions.

Procurement prices in the health sector vary for reasons that are well known to administrators. Rates differ with volume, tender terms, supply contracts, transport and taxes. A hospital that buys in bulk through a tender may secure a lower rate than a smaller nursing home that buys in small lots. A single product may therefore have more than one landing price across institutions or even within the same institution over time.

That variation raises practical questions about what figure should appear on a bill. Whether the relevant figure is the last purchase price, the weighted average for a period, or the price under a specific rate contract can affect both accuracy and fairness. The government will need to address such detail if it decides to proceed with disclosure after re-examination.

There is also the question of confidentiality of commercial terms. Hospitals negotiate rates with distributors and manufacturers. Disclosure of those rates on individual bills would make negotiated prices visible to patients and, indirectly, to competitors. The court may be asked to weigh that commercial interest against the public interest in transparency.

Similar debates have arisen in other parts of the health sector. Authorities have in the past asked establishments to display rates for procedures, to issue itemised bills, and to prescribe generic names where possible. Disclosure of trade margins on drugs and devices has been discussed at policy level. Each step has raised the same core issue of how much information helps the patient without making routine compliance unworkable.